INI-CET EXAM -2025: Which of these drug combinations is recommended for HIV pre-exposure prophylaxis (PrEP) in individuals at hig…

INI-CET EXAM -2025

Pharmacology

Easy

Appeared in: INI-CET EXAM -2025

Explanation

The standard and most recommended regimen for HIV PrEP is a daily oral pill combining Tenofovir and Emtricitabine.
This combination is available as Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) or Tenofovir Alafenamide/Emtricitabine (TAF/FTC).
Major health organizations like the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) approve this combination for its high efficacy in reducing the risk of acquiring HIV in high-risk individuals.
Studies show that daily PrEP with this combination reduces the risk of getting HIV from sex by over 90%.

Option A: Tenofovir used alone (monotherapy) is less effective than when combined with Emtricitabine and is not the recommended standard of care for PrEP.
Option B: Although Lamivudine is chemically similar to Emtricitabine and this combination is sometimes used as an alternative, the combination of Tenofovir + Emtricitabine is the most widely studied, approved, and recommended first-line regimen for PrEP.
Option C: This is an older drug combination primarily used for HIV treatment (ART), not prevention (PrEP). Zidovudine is associated with more significant side effects, such as anemia and lipoatrophy, and is not a preferred agent for PrEP.

Visual 1: Chart: Comparison of common antiretroviral combinations for HIV PrEP and Treatment, highlighting their components, primary use (prevention vs. treatment), and key side effects.

Clinical Relevance

Nursing practice connection: Knowing Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP) helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
Nurses are central to PrEP management. Responsibilities include patient education on strict adherence, counseling on continued safe sex practices, monitoring for side effects (especially renal function and bone density with TDF), and ensuring regular HIV testing (typically every 3 months).
A critical safety step is to confirm a person is HIV-negative before initiating PrEP. Starting PrEP in an individual with undiagnosed acute HIV can lead to the development of drug-resistant virus strains.
What if? If a patient has pre-existing kidney disease or significant risk factors for it, the combination of Tenofovir Alafenamide/Emtricitabine (TAF/FTC) is generally preferred over the Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) regimen due to its lower risk of nephrotoxicity and adverse effects on bone mineral density.

How to Approach the Question

First, identify the core of the question: the specific drug regimen for HIV Pre-Exposure Prophylaxis (PrEP).
Recognize the crucial difference between PrEP (prevention in HIV-negative individuals) and ART (treatment in HIV-positive individuals). The question is about prevention.
Recall or analyze the standard-of-care medications for PrEP. The backbone of modern PrEP involves a two-drug combination.
Evaluate each option. The combination of Tenofovir and Emtricitabine is the most well-established and recommended regimen.
Eliminate options that are incorrect. Zidovudine-based regimens are primarily for treatment and have a less favorable side-effect profile for prevention. Monotherapy is less effective than combination therapy.

Concept Tested & Keywords

Concept Tested: Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP)
Stem keywords: HIV, pre-exposure prophylaxis, PrEP, drug combinations, high risk
Lead-in keywords: Which of these

QdHlUnzmicM6467jw966qd